Literature DB >> 8497042

Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin.

P C Roberts1, W Garten, H D Klenk.   

Abstract

The role of three N-linked glycans which are conserved among various hemagglutinin (HA) subtypes of influenza A viruses was investigated by eliminating the conserved glycosylation (cg) sites at asparagine residues 12 (cg1), 28 (cg2), and 478 (cg3) by site-directed mutagenesis. An additional mutant was constructed by eliminating the cg3 site and introducing a novel site 4 amino acids away, at position 482. Expression of the altered HA proteins in eukaryotic cells by a panel of recombinant vaccinia viruses revealed that rates and efficiency of intracellular transport of HA are dependent upon both the number of conserved N-linked oligosaccharides and their respective positions on the polypeptide backbone. Glycosylation at two of the three sites was sufficient for maintenance of transport of the HA protein. Conserved glycosylation at either the cg1 or cg2 site alone also promoted efficient transport of HA. However, the rates of transport of these mutants were significantly reduced compared with the wild-type protein or single-site mutants of HA. The transport of HA proteins lacking all three conserved sites or both amino-terminally located sites was temperature sensitive, implying that a polypeptide folding step had been affected. Analysis of trimer assembly by these mutants indicated that the presence of a single oligosaccharide in the stem domain of the HA molecule plays an important role in preventing aggregation of molecules in the endoplasmic reticulum, possibly by maintaining the hydrophilic properties of this domain. The conformational change observed after loss of all three conserved oligosaccharides also resulted in exposure of a normally mannose-rich oligosaccharide at the tip of the large stem helix that allowed its conversion to a complex type of structure. Evidence was also obtained suggesting that carbohydrate-carbohydrate interactions between neighboring oligosaccharides at positions 12 and 28 influence the accessibility of the cg2 oligosaccharide for processing enzymes. We also showed that terminal glycosylation of the cg3 oligosaccharide is site specific, since shifting of this site 4 amino acids away, to position 482, yielded an oligosaccharide that was arrested in the mannose-rich form. In conclusion, carbohydrates at conserved positions not only act synergistically by promoting and stabilizing a conformation compatible with transport, they also enhance trimerization and/or folding rates of the HA protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497042      PMCID: PMC237641          DOI: 10.1128/JVI.67.6.3048-3060.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Structure and assembly of hemagglutinin mutants of fowl plague virus with impaired surface transport.

Authors:  W Garten; C Will; K Buckard; K Kuroda; D Ortmann; K Munk; C Scholtissek; H Schnittler; D Drenckhahn; H D Klenk
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

2.  Deacylation of the hemagglutinin of influenza A/Aichi/2/68 has no effect on membrane fusion properties.

Authors:  D A Steinhauer; S A Wharton; D C Wiley; J J Skehel
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

3.  Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2).

Authors:  M Ohuchi; M Orlich; R Ohuchi; B E Simpson; W Garten; H D Klenk; R Rott
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

4.  Role of asparagine-linked glycosylation in human immunodeficiency virus type 1 transmembrane envelope function.

Authors:  D A Dedera; R L Gu; L Ratner
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

5.  Release of putative exocytic transport vesicles from perforated MDCK cells.

Authors:  M K Bennett; A Wandinger-Ness; K Simons
Journal:  EMBO J       Date:  1988-12-20       Impact factor: 11.598

6.  Interactions of misfolded influenza virus hemagglutinin with binding protein (BiP).

Authors:  S M Hurtley; D G Bole; H Hoover-Litty; A Helenius; C S Copeland
Journal:  J Cell Biol       Date:  1989-06       Impact factor: 10.539

7.  Addition of carbohydrate side chains at novel sites on influenza virus hemagglutinin can modulate the folding, transport, and activity of the molecule.

Authors:  P Gallagher; J Henneberry; I Wilson; J Sambrook; M J Gething
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

8.  Differential effects of mutations in three domains on folding, quaternary structure, and intracellular transport of vesicular stomatitis virus G protein.

Authors:  R W Doms; A Ruusala; C Machamer; J Helenius; A Helenius; J K Rose
Journal:  J Cell Biol       Date:  1988-07       Impact factor: 10.539

9.  Folding of influenza hemagglutinin in the endoplasmic reticulum.

Authors:  I Braakman; H Hoover-Litty; K R Wagner; A Helenius
Journal:  J Cell Biol       Date:  1991-08       Impact factor: 10.539

10.  Selective degradation of T cell antigen receptor chains retained in a pre-Golgi compartment.

Authors:  C Chen; J S Bonifacino; L C Yuan; R D Klausner
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more
  51 in total

1.  Expression of stable human O-glycan core 2 beta-1,6-N-acetylglucosaminyltransferase in Sf9 insect cells.

Authors:  D Toki; M Sarkar; B Yip; F Reck; D Joziasse; M Fukuda; H Schachter; I Brockhausen
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

3.  Targeted infection of endothelial cells by avian influenza virus A/FPV/Rostock/34 (H7N1) in chicken embryos.

Authors:  A Feldmann; M K Schäfer; W Garten; H D Klenk
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein.

Authors:  M Ohuchi; A Cramer; M Vey; R Ohuchi; W Garten; H D Klenk
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

5.  Proteolytic cleavage of wild type and mutants of the F protein of human parainfluenza virus type 3 by two subtilisin-like endoproteases, furin and Kex2.

Authors:  D Ortmann; M Ohuchi; H Angliker; E Shaw; W Garten; H D Klenk
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

Review 6.  Broadly neutralizing antibodies against influenza viruses.

Authors:  Nick S Laursen; Ian A Wilson
Journal:  Antiviral Res       Date:  2013-04-09       Impact factor: 5.970

7.  N-Glycosylation of Seasonal Influenza Vaccine Hemagglutinins: Implication for Potency Testing and Immune Processing.

Authors:  Yanming An; Lisa M Parsons; Ewa Jankowska; Darya Melnyk; Manju Joshi; John F Cipollo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

8.  Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

9.  Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport.

Authors:  K Takeuchi; R A Lamb
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Influence of N-glycans on processing and biological activity of the nipah virus fusion protein.

Authors:  Markus Moll; Andreas Kaufmann; Andrea Maisner
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.